Association of Statin Use With the In-Hospital Outcomes of 2019-Coronavirus Disease Patients: A Retrospective Study

Fan, Yongzhen; Guo, Tao; Yan, F.; Gong, Ming; Zhang, Xin A.; Li, Chenze; He, Tao; Luo, Hesheng; Zhang, Lin; Chen, Ming; Wu, Xiaoyan; Wang, Hairong; Deng, Ke‐Qiong; Bai, Jiao; Cai, Lin; Lu, Zhibing

doi:10.3389/fmed.2020.584870

Cited by 32 publications

(50 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of our study compare favorably with those of other observational studies of inpatient treatment of COVID-19 patients with statins and ACEIs/ARBs (Table 3) [64][65][66][67][68]. Similar to our study, these reports show that in-hospital treatment with statins alone or ACEIs/ARBs alone improved survival.…”

Section: Discussionsupporting

confidence: 90%

“…In these studies, treatment was ascertained largely on the basis of outpatient (not inpatient) information. For example, in a study of 247 statin-treated COVID-19 patients, 46% of treatments were initiated after hospital admission and yet 29% of all statin treatments were discontinued because of elevated liver function or creatine kinase tests [66]. Another study showed that outpatient statin treatment was associated with decreased COVID-19 mortality, although only 77% of outpatient-treated patients continued statin treatment after hospital admission [71].…”

Section: Discussionmentioning

confidence: 99%

“…Most investigators who have reported observational studies showing that statin and/or ACEI/ARB treatment reduces COVID-19 mortality have called for randomized controlled trials (RCTs) to confirm their findings [e.g., 64,66,67,70,71]. Some investigators insist that RCTs are essential [91,92].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs

Byttebier¹,

Belmans²,

Alexander³

et al. 2021

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic has disrupted life throughout the world. Newly developed vaccines promise relief to people who live in high-income countries, although vaccines and expensive new treatments are unlikely to arrive in time to help people who live in low-and middle-income countries. The pathogenesis of COVID-19 is characterized by endothelial dysfunction. Several widely available drugs like statins, ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have immunometabolic activities that (among other things) maintain or restore endothelial cell function. For this reason, we undertook an observational study in four Belgian hospitals to determine whether in-hospital treatment with these drugs could improve survival in 959 COVID-19 patients. We found that treatment with statins and ACEIs/ARBs reduced 28-day mortality in hospitalized COVID-19 patients. Moreover, combination treatment with these drugs resulted in a 3-fold reduction in the odds of hospital mortality (OR=0.33; 95% CI 0.17-0.69). These findings were in general agreement with other published studies. Additional observational studies and clinical trials are needed to convincingly show that in-hospital treatment with statins, ACEIs/ARBs, and especially their combination saves lives.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs

Byttebier¹,

Belmans²,

Alexander³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…We further examined 26 full-text articles and searched the references of relevant articles, retrieving 2 additional publications. Finally, 22 studies met all inclusion criteria [ 1 , 9 , 10 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ]. The flow diagram of the systematic articles search is presented in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

Statin Use Is Associated with a Decreased Risk of Mortality among Patients with COVID-19

Lee

et al. 2021

JCM

View full text Add to dashboard Cite

Background: Recent epidemiological studies remain controversial regarding the association between statin use and reducing the risk of mortality among individuals with COVID-19. Objective: The objective of this study was to clarify the association between statin use and the risk of mortality among patients with COVID-19. Methods: We conducted a systematic articles search of online databases (PubMed, EMBASE, Scopus, and Web of Science) between 1 February 2020 and 20 February 2021, with no restriction on language. The following search terms were used: “Statins” and “COVID-19 mortality or COVID19 mortality or SARS-CoV-2 related mortality”. Two authors individually examined all articles and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for study inclusion and exclusion. The overall risk ratio (RRs) with 95% confidence interval (CI) was calculated to show the strength of the association and the heterogeneity among the studies was presented Q and I2 statistic. Results: Twenty-eight studies were assessed for eligibility and 22 studies met the inclusion criteria. Statin use was associated with a significantly decreased risk of mortality among patients with COVID-19 (RR adjusted = 0.64; 95% CI: 0.57–0.72, p < 0.001). Moreover, statin use both before and after the admission was associated with lowering the risk of mortality among the COVID-19 patients (RR adjusted;before = 0.69; 95% CI: 0.56–0.84, p < 0.001 and RR adjusted;after = 0.57; 95% CI: 0.54–0.60, p < 0.001). Conclusion: This comprehensive study showed that statin use is associated with a decreased risk of mortality among individuals with COVID-19. A randomized control trial is needed to confirm and refute the association between them.

show abstract

“…3 Recent clinical data reported that statins are beneficial in reducing mortality of COVID-19. [4][5][6][7][8][9][10][11][12] In the present study, we retrospectively investigated the association between statin use prior to the diagnosis of COVID-19 and the severity of COVID-19 in a high-risk T he current pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with chronic cardiovascular disease and cardiovascular risk factors are more likely to be critical if infected with COVID-19.…”

mentioning

confidence: 99%

Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors

Ikari

Matsue

Torii

et al. 2021

Circ J

View full text Add to dashboard Cite

Background: Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19). Methods and Results:In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus. Conclusions:This study suggests the potential benefits of statins use against COVID-19.

show abstract

Association of Statin Use With the In-Hospital Outcomes of 2019-Coronavirus Disease Patients: A Retrospective Study

Cited by 32 publications

References 30 publications

Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs

Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs

Statin Use Is Associated with a Decreased Risk of Mortality among Patients with COVID-19

Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors

Contact Info

Product

Resources

About